Intestinal anti-inflammatory effect of the probiotic Saccharomyces boulardii in DSS-induced colitis in mice: Impact on microRNAs expression and gut microbiota composition

Rodríguez-Nogales, Alba; Algieri, Francesca; Garrido-Mesa, José; Vezza, Teresa; Utrilla, M. Pilar; Chueca, Natalia; García, Féderico; Rodríguez-Cabezas, M. Elena; Gálvez, Júlio

doi:10.1016/j.jnutbio.2018.08.005

Cited by 108 publications

(79 citation statements)

References 83 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Besides, probiotics have a beneficial therapeutic role in inflammatory bowel disease. As shown by Rodriguez-Nogaleset et al (112), the probiotic Saccharomyces boulardii increases intestinal bacteria diversity and alleviates the ecological imbalance of intestinal flora, so as to ameliorate and control the complex pathogenesis of inflammatory bowel disease. In terms of the underpinning immune mechanism, S. boulardii reduces the production of proinflammatory factors IL-1β and transforming growth factor β, thus inhibiting the inflammatory response.…”

Section: Intestinal Flora Can Be Used To Reconstruct Regional Immunitmentioning

confidence: 99%

“…For example, this yeast species inhibits expression of miR-155 and miR-223, which are increased in inflammatory bowel disease. Perhaps these changes in miRNA levels also play a role in the alleviation of diseases (112). As another example, Lactobacillus plantarum ZLP001 impacts the composition of the intestinal microflora, and increases the abundance of butyrate-producing bacteria such as Anaerotruncus and Faecalibacterium in the 30-day trial (113).…”

Section: Intestinal Flora Can Be Used To Reconstruct Regional Immunitmentioning

confidence: 99%

See 1 more Smart Citation

Intestinal Flora and Disease Mutually Shape the Regional Immune System in the Intestinal Tract

et al. 2020

View full text Add to dashboard Cite

The intestinal tract is the largest digestive organ in the human body. It is colonized by, and consistently exposed to, a myriad of microorganisms, including bifidobacteria, lactobacillus, Escherichia coli, enterococcus, clostridium perfringens, and pseudomonas. To protect the body from potential pathogens, the intestinal tract has evolved regional immune characteristics. These characteristics are defined by its unique structure, function, and microenvironment, which differ drastically from those of the common central and peripheral immune organs. The intestinal microenvironment created by the intestinal flora and its products significantly affects the immune function of the region. In turn, specific diseases regulate and influence the composition of the intestinal flora. A constant interplay occurs between the intestinal flora and immune system. Further, the intestinal microenvironment can be reconstructed by probiotic use or microbiota transplantation, functioning to recalibrate the immune homeostasis, while also contributing to the treatment or amelioration of diseases. In this review, we summarize the relationship between the intestinal flora and the occurrence and development of diseases as an in-turn effect on intestinal immunity. We also discuss improved immune function as it relates to non-specific and specific immunity. Further, we discuss the proliferation, differentiation and secretion of immune cells, within the intestinal region following remodeling of the microenvironment as a means to ameliorate and treat diseases. Finally, we suggest strategies for improved utilization of intestinal flora.

show abstract

Section: Intestinal Flora Can Be Used To Reconstruct Regional Immunitmentioning

confidence: 99%

Section: Intestinal Flora Can Be Used To Reconstruct Regional Immunitmentioning

confidence: 99%

Intestinal Flora and Disease Mutually Shape the Regional Immune System in the Intestinal Tract

et al. 2020

View full text Add to dashboard Cite

show abstract

“…These results indicated that S. boulardii mafic-1701 has beneficial effects on intestinal inflammation. Similarly, it has been previously shown that S. boulardii administration was significantly decreased mRNA expression of cytokines including interleukin-1β and interleukin-12 [25]. nuclear factor kappa B (NF-κB) is a pivotal regulator of innate immune responses in the gut [8].…”

Section: Discussionmentioning

confidence: 84%

Administration of Saccharomyces boulardii mafic-1701 improves growth performance, promotes antioxidant capacity, alleviates intestinal inflammation and modulates gut microbiota in weaned piglets

Zhang

Bao

Wang

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Probiotics seem to be an alternative to antibiotics for improving animal's health and intestinal development. Saccharomyces boulardii ( S. boulardii ) is a well-known probiotic. However, only few studies have been performed examining the effects of S. boulardii on weaned piglets . Therefore, this study was conducted to investigate the effects of dietary S. boulardii mafic-1701 on growth performance, antioxidant parameters, inflammation and intestinal microbiota in weaned piglets, using aureomycin as positive control. One hundred and eight piglets were randomly divided into three dietary treatment groups: (1) basal diet (CON); (2) basal diet supplemented with 75 mg/kg aureomycin (ANT); (3) basal diet supplemented with 1 × 10 8 CFU/kg S. boulardii mafic-1701 (SB). Results: Compared to CON, the supplementation with S. boulardii mafic-1701 improved feed efficiency over the entire 28 days ( P < 0.01) and decreased the rate of diarrhea during the first week ( P < 0.05). Total superoxide dismutase concentration was markedly increased in piglets with S. boulardii mafic-1701 ( P < 0.01). Moreover, compared with CON, SB increased the concentration of interleukin-4 in ileum ( P < 0.05), while the level of pro-inflammatory cytokines interleukin-6 ( P < 0.01) and tumor necrosis factor ( P < 0.01) were decreased in jejunum. SB increased the abundance of Bacillus and Ruminococcaceae ( P < 0.05), whereas the population of Clostridiaceae were decreased ( P < 0.05). Furthermore, the analysis of microbiota metabolites showed that S. boulardii mafic-1701 administration increased the concentration of formate and isobutyrate in cecum to maintain a stable microbiota and gut health ( P < 0.05). Conclusion: This study indicated that S. boulardii mafic-1701 supplementation could improve growth performance, alleviate the severity of diarrhea in weaned piglets, which may be associated with S. boulardii mafic-1701 promoted antioxidant activity, anti-inflammatory responses and microbi al ecology of piglets.

show abstract

“…The expression of inflammatory markers (IL‐1β, IL‐12) and epithelial‐integrity related proteins (TGFβ, ICAM1) in the colon alters the expression of microRNA, changes in the ratio of Firmicutes to Bacteroides induced by DSS (Rodriguez‐Nogales et al . 2018). Bacillus coagulans MTCC 5856 can improve depression and gastrointestinal symptoms in patients with severe IBS (Majeed et al .…”

Section: The Mechanism Of Action Of Gut Bacteria In Intestinal Diseasmentioning

confidence: 99%

Gut dysbacteriosis and intestinal disease: mechanism and treatment

Meng

Zhang

Cao³

et al. 2020

J. Appl. Microbiol.

View full text Add to dashboard Cite

Summary The gut microbiome functions like an endocrine organ, generating bioactive metabolites, enzymes or small molecules that can impact host physiology. Gut dysbacteriosis is associated with many intestinal diseases including (but not limited to) inflammatory bowel disease, primary sclerosing cholangitis‐IBD, irritable bowel syndrome, chronic constipation, osmotic diarrhoea and colorectal cancer. The potential pathogenic mechanism of gut dysbacteriosis associated with intestinal diseases includes the alteration of composition of gut microbiota as well as the gut microbiota–derived signalling molecules. The many correlations between the latter and the susceptibility for intestinal diseases has placed a spotlight on the gut microbiome as a potential novel target for therapeutics. Currently, faecal microbial transplantation, dietary interventions, use of probiotics, prebiotics and drugs are the major therapeutic tools utilized to impact dysbacteriosis and associated intestinal diseases. In this review, we systematically summarized the role of intestinal microbiome in the occurrence and development of intestinal diseases. The potential mechanism of the complex interplay between gut dysbacteriosis and intestinal diseases, and the treatment methods are also highlighted.

show abstract

Intestinal anti-inflammatory effect of the probiotic Saccharomyces boulardii in DSS-induced colitis in mice: Impact on microRNAs expression and gut microbiota composition

Cited by 108 publications

References 83 publications

Intestinal Flora and Disease Mutually Shape the Regional Immune System in the Intestinal Tract

Intestinal Flora and Disease Mutually Shape the Regional Immune System in the Intestinal Tract

Administration of Saccharomyces boulardii mafic-1701 improves growth performance, promotes antioxidant capacity, alleviates intestinal inflammation and modulates gut microbiota in weaned piglets

Gut dysbacteriosis and intestinal disease: mechanism and treatment

Contact Info

Product

Resources

About